Metastatic Nasopharyngeal Carcinoma research hub

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

This study looks at adding a new drug, relatlimab, to current treatments for nasopharyngeal cancer that has come back or spread. The aim is to see if this addition can help keep the cancer from growing or spreading for longer.